Timothy Skelton, MD
Internal Medicine · Biloxi, MSNPI 1598867350
Payments from drug & device makers
Across 468 payments — averaging $15.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$1K
- Boehringer Ingelheim$847
- Pfizer$554
- Novo Nordisk$520
- Bayer$336
- plus $2K from 29 others
What the payments were for
- Food & beverage$7,13799%
- Education$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 132 | $1,777 |
| AstraZeneca | 58 | $1,003 |
| Boehringer Ingelheim | 57 | $847 |
| Pfizer | 35 | $554 |
| Novo Nordisk | 32 | $520 |
| Bayer | 22 | $336 |
| Lilly USA, LLC | 20 | $334 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $274 |
| GSK | 10 | $172 |
| Amgen | 9 | $153 |
| Merck | 10 | $146 |
| Astellas Pharma US Inc | 9 | $144 |
| Johnson & Johnson | 10 | $143 |
| Abbott | 6 | $106 |
| Sanofi-aventis U.S. LLC | 5 | $80 |
| Idorsia Pharmaceuticals US Inc | 4 | $64 |
| Novartis | 4 | $58 |
| Exact Sciences | 3 | $52 |
| Sumitomo Pharma America, Inc. | 2 | $47 |
| Viatris Specialty LLC | 2 | $42 |
| Daiichi Sankyo Inc. | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Endo Pharmaceuticals Inc. | 2 | $33 |
| Dexcom, Inc. | 2 | $32 |
| Genentech USA, Inc. | 1 | $25 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $25 |
| Gilead | 1 | $22 |
| PBG Puerto Rico LLC | 1 | $21 |
| Corcept Therapeutics | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Shield Therapeutics Inc | 1 | $14 |
How this compares
$7,196 in reported general payments places this provider in the 90th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 88 | $139,298 |
| JardianceEmpagliflozin | 105 | $122,869 |
| EliquisApixaban | 34 | $45,892 |
| XareltoRivaroxaban | 39 | $45,322 |
| JanuviaSitagliptin Phosphate | 34 | $41,134 |
| Tresiba Flextouch U-100Insulin Degludec | 43 | $37,530 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $29,184 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $19,205 |
| TradjentaLinagliptin | 14 | $18,265 |
| FarxigaDapagliflozin Propanediol | 14 | $17,582 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $16,624 |
| MyrbetriqMirabegron | 18 | $15,855 |
| EntrestoSacubitril/Valsartan | 11 | $15,455 |
| LinzessLinaclotide | 13 | $12,041 |
| Spiriva RespimatTiotropium Bromide | 20 | $10,269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $847 | $151,403139 claims |
| Novo NordiskOzempic | $520 | $139,29888 claims |
| MerckJanuvia, Janumet Xr | $146 | $47,38649 claims |
| PfizerEliquis | $554 | $45,89234 claims |
| Johnson & JohnsonXarelto | $143 | $45,32239 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $1,003 | $36,78729 claims |
| GSKTrelegy Ellipta | $172 | $29,18435 claims |
| Astellas Pharma US IncMyrbetriq | $144 | $15,85518 claims |
| NovartisEntresto | $58 | $15,45511 claims |
| AbbVieLinzess, Synthroid | $1,777 | $13,40225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Biloxi
- Magdy Gorgi-MikhailBiloxi$157K
- Dawn HansenBiloxi$9K
- James HallBrookhaven$4.8M
- Bob HutchinsJackson$4.6M
- Sidney GortonBelzoni$571K
- David PendleyGulfport$336K
- Sarah KerutJackson$319K
- Gabriel HernandezJackson$196K
- Kelly WilkinsonJackson$183K
- Christina BarlowJackson$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.